Rhonda Rhyne

Rhonda Rhyne General Information

Biography

Ms. Rhonda Rhyne serves as Chief Executive Officer, Chief Translational Officer, President, and Board Member at Prevencio. She served as Board Member at Aminex Therapeutics. She also served as Board Member at OtoNexus Medical Technologies. She has more than 25 years of experience in health care with both public and private industry companies, as well as experience as a clinical pharmacist. She was previously President of CardioDynamics, a publicly-traded medical device company sold to SonoSite Inc. in 2009. Prior to CardioDynamics, she held positions of President & CEO, VP of Sales and Marketing, and Board Director at Culture Technology, Inc., a privately-held biotechnology company, as well as positions at GE Health Care and Cardiac Science. She is the principal of Rhyne Life Sciences Consulting, a consultancy practice focused on emerging life science technologies. She also serves on the Board of Directors and Audit Committee for La Jolla Institute of Allergy and Immunology, Deeds from the Heart, and Washington State University College of Pharmacy Dean's Advisory Council.